Dedicated to Developing Effective Therapeutics to Treat Neurodegenerative Disease






 
RECENT NEWS

 

July 13, 2014:

Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17  Read More...



December 4, 2012:

Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Stephen Jacobsen, Ph.D., joined the ALSP Scientific Advisory Board. Dr. Pierschbacher said “We are honored that
Steve has joined our team. His international stellar reputation for innovation in Alzheimer’s disease drug development and his in-depth unders
tanding of the pharmaceutical industry will help accelerate our program to the clinic.” Read More...

  

October 13-17, 2012: 

Dr. Greg Hook, VP Alzheimer’s Research, ALSP, debuted data on cathepsin B as a target for traumatic brain injury (TBI) and on methods of inhibiting cathepsin B to treat TBI at the Society of Neuroscience meeting in New Orleans, LA, October 13 – 17, 2012 .Read More...

 

September 5, 2012: 

Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Bernice Wells, MD, MBA, joined the ALSP Board of Directors.  Dr. Pierschbacher said “Bernice is truly an exceptional individual as she has extensive venture capital experience, pharmaceutical industry experience and is a physician.  Her business and technical insight will help insure ALSP succeeds.” Read More...

 

July 16-18, 2012: 

 Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Vancouver, Canada, July 16 – 18, 2012.  They provided data validating the protease cathepsin B as a key therapeutic target for treating Alzheimer’s disease, and demonstrating the oral efficacy of a cathepsin B inhibitor in an Alzheimer’s disease animal model representative of most Alzheimer’s disease patients. Read More...

 

May 14-15, 2012:  

The National Institute on Aging’s Alzheimer’s Disease Research Summit was held in Bethesda, MD, at which Health and Human Services Secretary Kathleen Sebelius released the ambitious national plan to fight Alzheimer’s disease called the National Alzheimer’s Project (NAPA), which set forth five goals, including the development of an effective treatment for Alzheimer’s disease by 2025.  The meeting called for public comment on how to achieve those goals.  Dr. Greg Hook, VP Alzheimer’s Research, and Dr. Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, attended and participated in the meeting and provided recommendations to NAPA. Read More...

 

April 21 - 25, 2012:

 Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, presented at THE AMERICAN SOCIETY FOR MOLECULAR BIOCHEMISTRY AND MOLECULAR BIOLOGY in San Diego, CA. Read More…

 

To read more about previous ALSP Inc. news and events, please click here.
RECENT NEWS
 
July 13, 2014:
Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17  Read More...
RECENT NEWS
 
July 13, 2014:

RECENT NEWS

September, 2018: American Life Science Pharmaceuticals (ALSP) is pleased to announce that it recently has been awarded a Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disease (NINDS) at the National Institutes of Health, Bethesda, MD.  The grant is entitled “Cathepsin B inhibitor Drug Development for Traumatic Brain Injury” and is led by Principal Investigator, Dr. Greg Hook, JD, Ph.D., Vice President of Research at ALSP.  The grant is a collaboration with the University of California, San Diego (UCSD), which has a grant subcontract, led by Vivian Hook, Ph.D., Distinguished Professor, The Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD.  The grant will establish proof-of-principal for the development of an entirely new class of TBI therapeutics.

April, 2017: ALSP announced that it has had the great good fortune to have Steve Jacobsen, Ph.D. accept the position of CEO and take a seat on its Board. Steve has been advising the Company for a number of years and became available when he left his position as Senior Project Director of Neuroscience iMed at AstraZeneca. Steve brings with him many years' experience in drug development for neurodegeneration and a world class reputation in the space, and we are proud to welcome him onboard. Dr. Pierschbacher will remain with the Company and is very much looking forward to working with Steve in his new leadership capacity.

June, 2016: Vivian Hook, Ph.D., UCSD, and Gregory Hook, Ph.D., ALSP Inc., will present scientific papers at the National Neurotrauma Society Meeting, June 26-29, 2016, in Lexington, Kentucky, and at the Gordon Research Conference on Neurobiology of Brain Disorders, August 7-12, 2016, in Girona, Spain. 


resented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17  Read More...
Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17  Read More...
RECENT NEWS
 
July 13, 2014:
Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17  Read More...
RECENT NEWS
 
July 13, 2014:RECENT NEWS

OUR STORY
 
ALSP Inc. is a privately held company based in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on  traumatic brain injury (TBI) and Alzheimer's disease (AD). Our approach is to identify key enzymes in the brain, called neuroproteases, which produce biologically active peptides that are thought to cause the condition. Those enzymes become targets for screening compounds that inhibit the neuroproteases and thereby reduce production of the harmful peptides.

Since Drs. Katz, von Euler and Axelrod were awarded the Nobel Prize in Physiology or Medicine in 1970 for their discoveries concerning the humoral transmitters in the nerve terminals and the mechanism for their storage, release and inactivation, the process of studying neurotransmitters and the enzymes that produce them have flourished. By using this well-established process, we have identified a family of drugs that is highly effective at reversing the symptoms of neurodegenerative diseases, such as traumatic brain injury (TBI) and Alzheimer's disease (AD) in animal models of these conditions. We are advancing our lead compound into clinical trials and continuing our search for additional drugs to treat traumatic brain injury (TBI) as well as Alzheimer's disease (AD) and other devastating neurodegenerative diseases.

Follow Us On: